CAMBRIDGE, Mass. — Aug 4, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology. The peer-reviewed paper demonstrates how advanced artificial intelligence combined with comprehensive multi-omic analysis can successfully identify promising therapeutic targets in one of the rarest and least understood forms of head and neck cancer.

A new study led by Swansea University has laid bare the devastating impact that soaring infant formula milk prices are having on the health, finances, and mental wellbeing of UK parents and their children.

AMHERST, Mass. — Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress—and billions of dollars of industry investments—one area that has lagged behind is dosing, which is still one-size-fits-all. Now, researchers at the University of Massachusetts Amherst have developed an AI model that can inform treatment individualization by generating a patient’s radiation dose map that matches gold-standard accuracy in under 23 seconds.

In a study published recently in Cancer Research, scientists in the lab of Prof. Ayelet Erez at the Weizmann Institute of Science found that sildenafil, Viagra’s active ingredient, may restrict cancer metastasis through a newly discovered biological mechanism.

First results from the multicenter FUSOMAP project, led by VHIO, support the potential use of Fusobacterium as a prognostic and predictive biomarker in patients with resectable stage I–III CRC.